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Introduction: The majority of patients with non-small cell lung
cancer (NSCLC) develop distant metastases. Epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors are capable of
reducing brain and adrenal metastases. However, the EGFR status
may be discordant between primary NSCLC and the corresponding
metastases.
Methods: Using fluorescence in situ hybridization (FISH) analysis,
the EGFR gene status was evaluated in a series of 38 cerebral or
adrenal metastases collected from two institutions and in the corre-
sponding primary tumors. Also, EGFR mutational analysis was
performed using direct sequencing on the cerebral metastases.
Results: EGFR FISH was positive in 28% of the primary tumors
and in 45% of the metastases (p  0.05). Among the seven cases
FISH-positive at the metastatic site but negative in the primary
tumor, six were brain metastases, and one was an adrenal metastasis;
all were polysomic for chromosome 7, none were amplified. No
EGFR mutations have been found in the cerebral metastases.
Conclusion: Because the molecular asset of EGFR may change
during the metastatic progression of NSCLC to brain (but not to
adrenal), the selection of patients with brain metastasis for specific
targeted therapies by EGFR FISH analysis should be performed on
metastatic lesions rather than on their corresponding primary tumors.
Key Words: FISH, EGFR polysomy, Brain metastases, Lung
cancer.
(J Thorac Oncol. 2009;4: 684–688)
Lung cancer is the most common cause of cancer death inboth men and women throughout the world. Disease stage
is usually advanced at presentation, median survival time is
stage dependent, and globally, the overall survival remains
poor. Lung cancer extrathoracic spread occurs more com-
monly to the bone, liver, adrenal gland, and brain. Approxi-
mately 40% of all patients with lung cancer suffer from brain
metastases in the course of their disease,1 although the fre-
quency of metastasis to the adrenal gland found at autopsy
ranges from 18 to 42%.2 Although patients with brain me-
tastases are generally treated with corticosteroids and whole-
brain radiation therapy, their prognosis is still disappointing.
Whole-brain radiation therapy extends survival by only 14 to
21 weeks, even when it achieves palliative improvement for
neurologic symptoms.3,4 Moreover, refractory brain metasta-
ses cause death in 25 to 50% of these patients.4 In the case of
adrenal metastases a palliative chemotherapy should be con-
sidered, even though most recent studies suggest the adrenal-
ectomy as a therapeutic option for patients with a single
metachronous or synchronous adrenal metastases with a en-
couraging 5-year survival rate of 25%.5
During the last few years, new molecularly targeted
agents aimed to inhibit specific pathways and key molecules
in tumor growth and progression have been developed. One
example of such a target is the epidermal growth factor
receptor (EGFR), a tyrosine kinase (TK) receptor, overex-
pressed in many human epithelial malignancies, including
non-small cell lung cancer (NSCLC)6,7 in which its expres-
sion is associated with poor survival.8 Ligand binding to
EGFR leads to receptor TK activation and to a series of
downstream signaling activation that mediate proliferation,
migration, invasion, and suppression of apoptosis.9 The
EGFR signaling can be blocked by small-molecule EGFR TK
inhibitors, such as gefitinib and erlotinib. These inhibitors
produce objective response rates of 12 to 27% in previously
treated or untreated advanced NSCLC.10–13 Interestingly,
some recent reports have demonstrated that gefitinib and
erlotinib are capable of reducing brain metastases from
NSCLC, sometimes with a dramatic improvement,14–17 and a
complete responsiveness was reported in a single case of a
Taiwanese female patient with an adrenal metastasis from
lung adenocarcinoma.18 Acquired mutations of EGFR gene in
exons 18 to 21 and EGFR gene copy number, which is
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assessed by fluorescence in situ hybridization (FISH), could
be used to predict a patient’s responsiveness.19,20 However,
an association of such molecular features with brain and
adrenal metastases is not well referenced, and the possibility
should be considered that the actual status of the EGFR gene
in the metastases could differ from that of the primary tumor.
The aim of the current study is to investigate possible
changes in the EGFR gene copy number between primary
lung cancer and the corresponding brain or adrenal metasta-
ses. These two metastatic sites were selected because of the
availability of a relatively large number of single secondary
lesions from two surgical series. In addition, the presence of
specific EGFR mutations was evaluated in the series of brain
metastases. We show that the EGFR gene gains, as detected
by FISH, are more frequent in brain (but not in adrenal)
metastases than in the corresponding primary tumors.
PATIENTS AND METHODS
Patients and Tissue Samples
Between January 2004 and December 2006 tumor spec-
imens from 80 consecutive patients with surgically excised
cerebral metastases from lung cancer were analyzed in the
Pathology Department of the San Giovanni Hospital (Turin,
Italy). Thirteen other patients affected by lung cancer under-
went adrenal metastasis resection at the San Luigi Gonzaga
Hospital (Orbassano, Turin, Italy). In 38 of these 93 cases,
representative paraffin blocks of either cerebral metastasis or
adrenal metastasis and of the corresponding primary tumor
were available. Primary tumor specimens were constituted by
alcohol-fixed and paraffin-embedded transthoracic fine-nee-
dle aspirate (FNA) in 12 cases, by formalin-fixed and paraf-
fin-embedded (FFPE) bronchial biopsies in three cases, and
by FFPE surgical specimens obtained from radical surgery in
23 cases, respectively. This study was approved by the
institutional ethical review board.
EGFR FISH Analysis
FISH analysis was performed on the 38 cerebral/adre-
nal metastasis and on the correspondent primary tumors.
Probes for EGFR (Vysis Inc., Downers Grove, IL) were used
for FISH according to the manufacturer’s instructions.
Briefly, sections were baked overnight at 56°C, deparaf-
finized in xylene, dehydrated in 100% ethanol, and air dried;
then they were pretreated in sodium thiocyanate for 20
minutes at 80°C and then with proteases for 15 minutes at
37°C; finally, they were washed in 2X SSC, dehydrated using
increasing ethanol (70%, 85%, 100%), and air dried. Speci-
mens were covered with 10 L of probe (LSI EGFR/CEP7
Dual color probe, Vysis Inc., Downers Grove, IL) and a glass
coverslip sealed with rubber cement, codenatured in Hybrite
System (Vysis Inc., Downers Grove, IL) for 10 minutes at
80°C, and overnight hybridized at 37°C. Finally, slides were
washed with posthybridization buffer at 73°C and counter-
stained with 4, 6-diamidino-2-phenylindole. Tumor sections
were first scanned at low power with a 4, 6-diamidino-2-
phenylindole filter to identify areas of optimal tissue diges-
tion and nonoverlapping nuclei. Patients were classified into
two strata: (i) FISH-negative, with no or low genomic gain
(four copies of the gene in 40% of cells) or (ii) FISH-
positive, with either a high level of polysomy (four copies
of the gene in 40% of cells) or with gene amplification.
Gene amplification was defined by the presence of tight gene
clusters, and a gene/chromosome per cell ratio two, or 15
copies of the gene per cell in10% of analyzed cells.20,21 For
the evaluation of the FISH results in primary tumor speci-
mens obtained from FNA and from bronchial biopsies we
considered as positive cutoff the presence of at least 10
neoplastic cells showing gene gain, as previously stated.22
DNA Extraction and Polymerase Chain
Reaction
Mutational analysis was performed in the 28 brain
metastases. Genomic DNA was extracted from four 10-m
thick sections of FFPE blocks. After deparaffinizing with
xylene-ethanol, specimens were incubated overnight at 55°C
in lysis buffer containing proteinase K (20 mg/ml) followed
by DNA isolation after phenol-isopropanol extraction. DNA
concentration was measured with a spectrophotometer (Bio-
Photomer Eppendorf AG, Hamburg, Germany). The quality
of DNA extracted from FFPE was tested by performing
amplification of a 300-bp fragment of the human major
histocompatibility complex class II DR gene with the fol-
lowing primers: DRBF 5-CCG GTC GAC TGT CCC CCC
AGC ACG TTT C-3 and DRBR 5-GAA TTC TCG CCG
CTG CAC TGT GAA GC-3. Polymerase chain reaction
(PCR) amplification of EGFR (exons 19 and 21) was per-
formed using the following primers: EGFR19F 5-CAA TAT
CAG CCT TAG GTG CGG CTC-3; EGFR19R 5-CAT AGA
AAG TGA ACA TTT AGG ATG TG-3; EGFR21F 5-CTA
ACG TTC GCC AGC CAT AAG TCC-3; EGFR21R 5-GCT
GCG AGC TCA CCC AGA ATG TCT GG-3. PCR was
performed in a total volume of 50L, containing 1X PCR buffer
(Tris-HCl 20 mM, KCl 50 mM), MgCl2 1.5 mM, 0.2 mM
dNTPs, 0.4 M each primer, 0.2 U TaqDNA polymerase (In-
vitrogen, Carlsbad, CA), and 500 ng of genomic DNA. Thermal
cycling conditions were 5 minutes at 94°C, followed by 40
cycles of 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 30
seconds, with a final extension step of 72°C for 7 minutes.
DNA Sequencing
PCR products were separated on a 2% agarose gel,
purified using the PCR clean-up gel extraction kit (Macherey-
Nagel, Dueren, Germany), and sequenced in both directions
by dye-terminator sequencing with the BigDye Terminator
v1.1 Sequencing Kit (Applied Biosystems, Foster City, CA).
Sequencing fragments were detected by capillary electro-
phoresis on an ABI Prism 310 DNA analyzer (Applied
Biosystems).
Statistical Analysis
Pearson’s correlation test confirmed by Spearman’s
correlation test was used to compare the EGFR status
between primary tumors and related metastatic sites and
statistical significance was defined as p 0.05. Statistical
analyses were performed using the “R 1.7.1” statistical
software package.
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RESULTS
Clinical and Pathologic Features
The characteristics of the 38 lung cancer patients are
reported in Table 1. The median age of patients at diagnosis
of metastasis was 66 years (with a range of 45–82 years). The
thirty-eight analyzed metastases were synchronous in 19
cases (50%) and metachronous in 19 cases (50%). There were
33 men and five women. Eighteen patients (47%) had ade-
nocarcinoma, seven (18%) squamous cell carcinoma, three
(8%) large cells carcinoma, three (8%) small cell carcinoma,
and seven (18%) had NSCLC not otherwise specified. In
particular, of the 28 patients with brain metastases, 10 had
adenocarcinoma (36%), seven squamous cell carcinoma
(25%), three large cells carcinoma (10%), three small cell
carcinoma (10%), and five (18%) had NSCLC not otherwise
specified. Of the 10 patients with adrenal metastases, eight
(80%) had adenocarcinoma and two (20%) had NSCLC not
otherwise specified.
None of the patients received prior EGFR-targeted
therapy.
EGFR FISH Analysis
EGFR FISH was assessable on 36 of the 38 archival
histologic and cytologic sections from the primary lung
cancer and on 37 of the 38 histologic sections from the
corresponding metastatic (brain or adrenal) sites. Three sam-
ples were inadequate because of a large amount of autofluo-
rescent hemosiderin or necrotic background. EGFR data
obtained by FISH analysis in the 35 primary NSCLC and
corresponding brain or adrenal metastases are shown in Table
2. EGFR FISH was positive in 28% (10 of 35) of the primary
tumors and in 45% (16 of 35) of the metastatic sites (p 
0.05). In particular, FISH was positive in 10 of 25 (40%)
brain metastases and in six of 10 (60%) adrenal metastases.
Among the 10 cases that were EGFR FISH positive in the
primary tumor, only two were amplified, whereas the others
were polysomic for Chromosome 7. The two cases with
EGFR amplification in the primary tumor confirmed their
status in the corresponding metastatic site. Among the seven
cases that were EGFR FISH positive in the metastatic site but
negative in the primary tumor, six were brain metastases, and
only one was an adrenal metastasis; all were polysomic for
Chromosome 7, and none were amplified (Figure 1). Nine of
the 35 cases (26%) were EGFR FISH positive for both the
primary tumor and the metastasis and 18 (51%) were negative
for both the primary tumor and the metastasis. Eight of the 35
cases (23%) showed primary tumor versus metastasis discor-
dance; in seven cases, EGFR FISH was positive in the
metastatic site but negative in the primary tumor, and one
sample was EGFR positive in the primary tumor but not in
the metastasis. Interestingly, the tissue source (and relative
availability of neoplastic cells) was not a major cause of
discrepancy, because among the eight discrepant cases, only
one consisted of cytologic FNA from the primary tumor,
whereas all other cases were represented by histologic spec-
imens (bronchial biopsies and surgical resections).
EGFR Mutation Status
Among the 28 brain metastases from lung cancer, no
specific EGFR mutation was detected in the analyzed exons
(19 and 21).
DISCUSSION
The majority of patients with NSCLC develop distant
metastases either at the time of the initial diagnosis or during
the disease progression. Several reports have shown that
EGFR specific tyrosine kinase inhibitors such as gefitinib and
erlotinib are capable of reducing brain and adrenal metastases
in NSCLC, sometimes with a highly dramatic response.14–17
Both mutations and amplifications or gene gains of EGFR
have been reported in association with clinical responses to
such drugs.19,20 A previous study demonstrated that EGFR
FISH analysis may be used as the first-choice laboratory test,
as an alternative to gene mutation analysis, for endoscopic
biopsies or cytologic specimens of NSCLC to select patients
TABLE 1. Patients Characteristics (n  38)
No. Patients Percentage
Age (yr)
Median (range) 66 (45–82)
Gender
Male 33 87
Female 5 13
Histology
Adenocarcinoma 18 47
Squamous cell carcinoma 7 18
Large cells carcinoma 3 8
Small cells carcinoma 3 8
NSCLC NOS 7 18
Stage at diagnosisa
I 7 18
II 8 21
III 8 21
IV 15 39
Metastatic sites analyzed
Brain 28 73
Adrenal 10 27
a Stage at the time of primary tissue sampling.
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
TABLE 2. Correlation Between EGFR FISH Status in Primary
Lung Cancer and Corresponding Metastatic (Brain or
Adrenal) Site
EGFR FISH in
Brain Mts
EGFR FISH in
Adrenal Mts
TotalFISH  FISH  FISH  FISH 
EGFR FISH in
primary tumor
FISH  14 6 4 1 25
FISH  1 4 0 5 10
Total 15 10 4 6 35
p  0.05 p  0.05
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization.
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for response.22 However, the issue of EGFR expression
consistency throughout the metastatic process for NSCLC is
not yet clear. In fact, the EGFR receptor status has been
determined in primary tumors, whereas data referring to the
distant metastases are almost nonexistent. A limited number
of studies23,24 reported that the correlation between EGFR
status in primary NSCLC cancer and in the corresponding
metastatic sites is relatively poor, suggesting a change during
metastatic progression. This discordance has been observed
also by Petersen et al.,25 who identified chromosomal imbal-
ances at the 7p11 region, to which the EGFR gene has been
mapped, by comparative genomic hybridization in a series of
paired primary tumor and metastases of NSCLC. A recent
study by the group of Kalikaki et al.26 found a substantial
discordance in EGFR and K-RAS mutational status between
the primary tumors and corresponding metastases in patients
with NSCLC. To the best of our knowledge, only one study
has performed EGFR FISH analysis on a selected series of 30
patients with NSCLC and the corresponding metastasis and
found that the EGFR gene copy number was discordant in a
significant proportion of cases.24 In our study, we aimed to
ascertain the EGFR status in metastatic brain or adrenal
lesions in comparison with the corresponding primary tu-
mors. Our results revealed a discordance in 23% of cases,
comparing primary tumors versus metastases. Brain me-
tastases acquired a specific EGFR gene gain (driven by a
high polysomy of chromosome 7) in six cases that were
FISH negative in the corresponding primary tumor, with
one case positive at FISH analysis in the primary tumor but
negative in the metastatic site. In adrenal metastases, only
one case acquired a specific EGFR gene gain, whereas the
other five cases were consistent with the EGFR status of
the primary lesions.
In our study, no specific EGFR mutations were found.
This frequency is lower than the frequencies reported by
other studies,27 and this surprising lack of EGFR mutation
was observed in a consistent series of 28 brain metastases
from lung cancer. However, in Italy, the expected occurrence
of EGFR mutations for nonselected NSCLCs is not higher
than 4.5%,28 i.e., 1/28 cases, at best. It might be speculated
that lung cancers that metastasize to the brain contain partic-
ular EGFR gene alterations characterized by polysomy of
chromosome 7 rather than by known EGFR mutations. This
observation seems to conform to the available data in the
literature, because recent studies suggest that EGFR muta-
tions, when present, are an early event in the development of
lung adenocarcinoma. Yoshida et al.29 showed that EGFR
mutations were present in 3% of atypical adenomatous hy-
perplasias, which is considered to be a precursor lesion of
lung adenocarcinoma. Tang et al.30 reported that nine of 21
patients carrying lung adenocarcinoma EGFR mutations also
had identical mutations in the histologically normal respira-
tory epithelium. Thus, EGFR mutations are likely to be an
early genetic alteration in the multistage carcinogenic pro-
cesses of lung adenocarcinoma, but different genetic alter-
ations responsible for metastases could be required. A recent
study from the group of Yatabe et al.31 reported that a specific
EGFR amplification may be acquired in association with
tumor progression, even if this group suggests that the selec-
tion of the metastatic clone could be defined by factors other
than amplification. Our study demonstrated that the develop-
ment of brain metastasis could be correlated with a trend to
acquire a specific EGFR gene gain, whereas the progression
to adrenal metastasis could be related to other molecular
mechanisms. However, it should be considered as an alter-
native explanation of our findings that tumor heterogeneity
might be responsible of the differences between primary and
metastatic tumors observed in our study. In fact, it has been
recently reported that even in a context of a high polysomy
there may be plenty of diploid cells, and—with special
reference to cytologic FNA specimens with paucicellular
material—the risk of underestimating FISH results has to be
taken into account.32,33 However, it should be underlined that
in our series only one of eight discrepant cases corresponded
to FNA sample of the primary tumor.
Our findings must be taken into account when consid-
ering the recent evidence of the efficacy of gefitinib and
erlotinib in the treatment of brain metastases from lung
cancer. Because the molecular asset of EGFR may change
during the metastatic progression, our data suggest that the
selection of patients for specific targeted therapies by EGFR
FISH analysis should, whenever possible, be performed on
metastatic lesions rather than on their corresponding primary
tumors.
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FIGURE 1. Dual-color FISH assays
using EGFR (red) and chromo-
some-7 centromere (CEP7, green)
probes: balanced disomy in the pri-
mary lung tumor (A) and high level
of polysomy 7 in the corresponding
brain metastasis (B).
Journal of Thoracic Oncology • Volume 4, Number 6, June 2009 Epidermal Growth Factor Receptor Gene
Copyright © 2009 by the International Association for the Study of Lung Cancer 687
REFERENCES
1. Rizzi A, Tondini M, Rocco G, et al. Lung cancer with a single brain
metastasis: therapeutic options. Tumori 1990;76:579–581.
2. Burt M, Heelan RT, Coit D, et al. Prospective evaluation of unilateral
adrenal masses in patients with operable non-small-cell lung cancer.
Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg
1994;107:584–588; discussion 588–589.
3. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R.
Ultra-rapid high dose irradiation schedules for the palliation of brain
metastases: final results of the first two studies by the Radiation Therapy
Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:1633–1638.
4. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of
previously irradiated recurrent primary brain tumors and brain metasta-
ses: initial report of radiation therapy oncology group protocol (90-05).
Int J Radiat Oncol Biol Phys 1996;34:647–654.
5. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenal-
ectomy for isolated synchronous versus metachronous adrenal metasta-
ses in non-small-cell lung cancer: a systematic review and pooled
analysis. J Clin Oncol 2008;26:1142–1147.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth
factor receptor in non-small-cell lung carcinomas: correlation between
gene copy number and protein expression and impact on prognosis.
J Clin Oncol 2003;21:3798–3807.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth
factor-related peptides and their receptors in human malignancies. Crit
Rev Oncol Hematol 1995;19:183–232.
8. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor
overexpression correlates with a poor prognosis in completely resected
non-small-cell lung cancer. Ann Oncol 2004;15:28–32.
9. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression,
signal pathway, and inhibitors in non-small cell lung cancer. Semin
Oncol 2002;29:38–44.
10. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized
phase II trial of gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin
Oncol 2003;21:2237–2246.
11. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor
of the epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: a randomized trial. JAMA
2003;290:2149–2158.
12. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor
response and survival with erlotinib in patients with non-small-cell lung
cancer. J Clin Oncol 2004;22:3238–3247.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med 2005;353:
123–132.
14. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib
is active in patients with brain metastases from non-small cell lung
cancer and response is related to skin toxicity. Lung Cancer 2005;47:
129–138.
15. Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain
metastases from non-small-cell lung cancer: review of 15 clinical cases.
Clin Lung Cancer 2004;6:123–128.
16. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino` L, Villa E.
Gefitinib in patients with brain metastases from non-small-cell lung
cancer: a prospective trial. Ann Oncol 2004;15:1042–1047.
17. Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial
metastases to erlotinib therapy. J Clin Oncol 2007;25:5024–5026.
18. Yeh KH, Yeh SH, Wan JP, Shen YC, Cheng AL. Somatic mutations in
epidermal growth factor receptor underlying complete responsiveness to
gefitinib in a Taiwanese female patient with metastatic adenocarcinoma
of lung. Anticancer Drugs 2005;16:739–742.
19. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal
growth factor receptor gene copy number detected by fluorescence in
situ hybridization associates with increased sensitivity to gefitinib in
patients with bronchioloalveolar carcinoma subtypes: a Southwest On-
cology Group Study. J Clin Oncol 2005;23:6838–6845.
20. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst 2005;97:643–655.
21. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—
molecular and clinical predictors of outcome. N Engl J Med 2005;353:
133–144.
22. Daniele L, Macri L, Schena M, et al. Predicting gefitinib responsiveness
in lung cancer by fluorescence in situ hybridization/chromogenic in situ
hybridization analysis of EGFR and HER2 in biopsy and cytology
specimens. Mol Cancer Ther 2007;6:1223–1229.
23. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal
growth factor receptor (EGFR) gene expression in primary non-small
cell lung cancer (NSCLC) and in fine-needle aspirates from distant
metastatic sites. J Thorac Oncol 2008;3:18–22.
24. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal
growth factor receptor gene and protein in primary non-small-cell-lung
cancer and metastatic sites: implications for treatment with EGFR-
inhibitors. Ann Oncol 2006;17:981–985.
25. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen
I. Chromosomal alterations in the clonal evolution to the metastatic stage
of squamous cell carcinomas of the lung. Br J Cancer 2000;82:65–73.
26. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR
and K-RAS gene status between primary tumours and corresponding
metastases in NSCLC. Br J Cancer 2008;99:923–929.
27. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations
in brain metastases of lung adenocarcinoma. Int J Cancer 2006;119:
1491–1494.
28. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-
small-cell lung cancer: analysis of a large series of cases and develop-
ment of a rapid and sensitive method for diagnostic screening with
potential implications on pharmacologic treatment. J Clin Oncol 2005;
23:857–865.
29. Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal
growth factor receptor gene in atypical adenomatous hyperplasia and
bronchioloalveolar carcinoma of the lung. Lung Cancer 2005;50:1–8.
30. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain
mutations are detected in histologically normal respiratory epithelium in
lung cancer patients. Cancer Res 2005;65:7568–7572.
31. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor
gene amplification is acquired in association with tumor progression of
EGFR-mutated lung cancer. Cancer Res 2008;68:2106–2111.
32. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA. Selecting lung
cancer patients for treatment with epidermal growth factor receptor
tyrosine kinase inhibitors by immunohistochemistry and fluorescence in
situ hybridization—why, when, and how? Clin Cancer Res 2006;12:
4409s–4415s.
33. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor
receptor gene analysis from cytological specimens of non-small-cell
lung cancers. Br J Cancer 2008;98:154–160.
Daniele et al. Journal of Thoracic Oncology • Volume 4, Number 6, June 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer688
